# Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)

> **NCT05871177** · NA · COMPLETED · sponsor: **IBSA Farmaceutici Italia Srl** · enrollment: 40 (actual)

## Conditions studied

- Peyronie Disease

## Interventions

- **DEVICE:** Pre-filled syringe of HiLow Hyaluronic Acid Sodium Salt

## Key facts

- **NCT ID:** NCT05871177
- **Lead sponsor:** IBSA Farmaceutici Italia Srl
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-21
- **Primary completion:** 2024-05-24
- **Final completion:** 2024-05-24
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05871177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05871177, "Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05871177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*